{"id":71505,"date":"2026-05-20T10:30:00","date_gmt":"2026-05-20T10:30:00","guid":{"rendered":"https:\/\/medsbase.com\/vip-vasoactive-intestinal-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"vip-vasoactive-intestinal-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/vip-vasoactive-intestinal-peptide\/","title":{"rendered":"VIP (Vasoactive Intestinal Peptide) \u2014 Research Grade"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is VIP (Vasoactive Intestinal Peptide)?<\/h3>\n

VIP<\/strong> (Vasoactive Intestinal Peptide; CAS 40077-57-4, MW 3,325.79 g\/mol) is a synthetic 28-amino-acid neuropeptide identical to native human VIP. Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2<\/sub> (C-terminal amide). Member of the VIP\/PACAP \/ secretin-glucagon superfamily<\/strong>. VIP acts at VPAC1 and VPAC2 receptors<\/strong> (Gs-coupled GPCRs) to produce a remarkable breadth of physiological effects: vasodilation, intestinal smooth-muscle relaxation, exocrine secretion, neurotransmitter modulation, sleep \/ circadian regulation, and broad anti-inflammatory \/ immune-modulating activity<\/strong>. Published research focuses on VIP’s role in Th2-polarised immune-modulation, autoimmune-disease pharmacology (RA, MS, IBD models), and neuroprotection. For laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Lyophilized \u226599% HPLC-verified VIP \u00b7 COA available on request \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide research-supply courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Compound Class<\/strong><\/td>\nSynthetic 28-aa neuropeptide; VPAC1 \/ VPAC2 receptor agonist; secretin-glucagon superfamily member<\/td>\n<\/tr>\n
CAS-nummer<\/strong><\/td>\n40077-57-4 (human VIP)<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2<\/sub> (HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2<\/sub>; 28 aa; C-terminal amide)<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n3,325.79 g\/mol<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC147<\/sub>H237<\/sub>N43<\/sub>O43<\/sub>S; MW 3326.78 g\/mol (28-aa free-amide neuropeptide).<\/td>\n<\/tr>\n
Werkingsmechanisme<\/strong><\/td>\nBinds VPAC1<\/strong> (broad distribution: lung, GI tract, T cells, brain, liver) and VPAC2<\/strong> (smooth muscle, mast cells, CNS) with similar affinity (low-nM KD<\/sub>). Both receptors are Gs-coupled \u2014 raises intracellular cAMP, activates PKA, drives downstream tissue-specific effects. Also has lower-affinity engagement of PAC1 receptor (the PACAP-preferred receptor).<\/td>\n<\/tr>\n
Form \/ Purity \/ Storage<\/strong><\/td>\nLyophilized white-to-off-white powder, \u226599% HPLC. Store 2\u20138 \u00b0C short-term, \u221220 \u00b0C long-term (\u226536 months). Reconstituted: 2\u20138 \u00b0C, use within 30 days.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nFor laboratory research use only. Not on the WADA Prohibited List. Aviptadil (synthetic VIP formulation) had inhalation-route Phase III research for COVID-19 ARDS but did not gain regulatory approval.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Mechanism of Action \u2014 VPAC1 \/ VPAC2 Pharmacology<\/h2>\n